

RÃ©gis Peffault de Latour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/585041/publications.pdf>

Version: 2024-02-01

137
papers

3,476
citations

201674

27
h-index

161849

54
g-index

139
all docs

139
docs citations

139
times ranked

4124
citing authors

#	ARTICLE	IF	CITATIONS
1	Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the SociÃ©tÃ© FranÃ§aise de Greffe de MoÃ«lle et de ThÃ©rapie Cellulaire. <i>Journal of Clinical Oncology</i> , 2008, 26, 2264-2271.	1.6	284
2	Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitorâ€œexperienced adult patients with PNH: the 302 study. <i>Blood</i> , 2019, 133, 540-549.	1.4	239
3	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	2.4	218
4	Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. <i>Blood</i> , 2013, 122, 4279-4286.	1.4	176
5	Long-term outcome of hepatitis C infection after bone marrow transplantation. <i>Blood</i> , 2004, 103, 1618-1624.	1.4	165
6	Similar outcome of upfrontâ€œunrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the <scp>UK</scp> Paediatric <scp>BMT</scp> Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of <scp>EBMT</scp>. <i>British Journal of Haematology</i> , 2015, 171, 585-594.	2.5	146
7	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. <i>Bone Marrow Transplantation</i> , 2022, 57, 1217-1239.	2.4	119
8	Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus noâ€œtreatment study. <i>American Journal of Hematology</i> , 2016, 91, 366-370.	4.1	110
9	Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. <i>British Journal of Haematology</i> , 2015, 169, 565-573.	2.5	104
10	Influence of Nucleated Cell Dose on Overall Survival ofâ€œUnrelated Cord Blood Transplantation for Patients with Severe Acquired Aplastic Anemia: A Study byâ€œEurocord and the Aplastic Anemia Working Party ofâ€œthe European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 78-85.	2.0	100
11	Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. <i>Nature Communications</i> , 2019, 10, 5695.	12.8	91
12	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. <i>Haematologica</i> , 2022, 107, 1045-1053.	3.5	87
13	How I treat MDS and AML in Fanconi anemia. <i>Blood</i> , 2016, 127, 2971-2979.	1.4	77
14	Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014, 99, 1574-1581.	3.5	73
15	Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1206-1211.	2.0	70
16	Allogeneic reactivityâ€œmediated endothelial cell complications after HSCT: a plea for consensual definitions. <i>Blood Advances</i> , 2019, 3, 2424-2435.	5.2	66
17	Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. <i>Haematologica</i> , 2018, 103, 212-220.	3.5	62
18	Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. <i>Lancet Haematology</i> , 2021, 8, e344-e354.	4.6	56

#	ARTICLE	IF	CITATIONS
19	Complement C5 inhibition in patients with COVID-19 - a promising target?. <i>Haematologica</i> , 2020, 105, 2847-2850.	3.5	53
20	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. <i>Blood Advances</i> , 2020, 4, 1942-1949.	5.2	49
21	Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. <i>Blood</i> , 2018, 132, 750-754.	1.4	44
22	Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?. <i>Blood</i> , 2018, 131, 1989-1992.	1.4	43
23	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (IACIF). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	2.4	39
24	Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. <i>British Journal of Haematology</i> , 2020, 191, 476-485.	2.5	38
25	Transplantation for bone marrow failure: current issues. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 90-98.	2.5	34
26	Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkinâ€™s lymphoma undergoing allogeneic haematopoietic cell transplantationâ€™ a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2018, 53, 400-409.	2.4	34
27	Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1223-1231.	3.5	34
28	Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party. <i>Haematologica</i> , 2016, 101, 884-890.	3.5	30
29	Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia. <i>American Journal of Hematology</i> , 2018, 93, 635-642.	4.1	26
30	Transplant results in adults with Fanconi anaemia. <i>British Journal of Haematology</i> , 2018, 180, 100-109.	2.5	25
31	Effect of Graft Source on Unrelated Donor Hemopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia after Reduced-Intensity or Nonmyeloablative Conditioning: A Study from the SociÃ©tÃ© Francaise de Greffe de Moelle et de ThÃ©rapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1059-1067.	2.0	24
32	HSCT may lower leukemia risk in ELANE neutropenia: a beforeâ€”after study from the French Severe Congenital Neutropenia Registry. <i>Bone Marrow Transplantation</i> , 2020, 55, 1614-1622.	2.4	24
33	Oneâ€”year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab. <i>European Journal of Haematology</i> , 2021, 106, 389-397.	2.2	24
34	Mainly Post-Transplant Factors Are Associated with Invasive Aspergillosis after Allogeneic Stem Cell Transplantation: A Study from the Surveillance des Aspergilloses Invasives en France and SociÃ©tÃ© Francaise de Greffe de Moelle et de ThÃ©rapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 354-361.	2.0	23
35	Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 392-400.	2.0	23
36	Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications. <i>Stem Cell Investigation</i> , 2017, 4, 40-40.	3.0	21

#	ARTICLE	IF	CITATIONS
37	Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial. <i>Blood</i> , 2020, 135, 227-229.	1.4	20
38	Identification of Distinct Immunophenotypes in Critically Ill Coronavirus Disease 2019 Patients. <i>Chest</i> , 2021, 159, 1884-1893.	0.8	20
39	Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria. <i>Seminars in Hematology</i> , 2018, 55, 124-129.	3.4	19
40	Utility and Safety of Liver Biopsy in Patients with Undetermined Liver Blood Test Anomalies after Allogeneic Hematopoietic Stem Cell Transplantation: A Monocentric Retrospective Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2523-2531.	2.0	19
41	Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia. <i>Haematologica</i> , 2019, 104, 256-262.	3.5	19
42	High Number of Memory T Cells Is Associated with Higher Risk of Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 569-574.	2.0	18
43	Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the SociÃ©tÃ© Francophone de Greffe de Moelle et de ThÃ©rapie Cellulaire. <i>American Journal of Hematology</i> , 2018, 93, 416-423.	4.1	18
44	Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry. <i>American Journal of Hematology</i> , 2019, 94, E37-E41.	4.1	17
45	Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers. <i>Haematologica</i> , 2018, 103, e103-e105.	3.5	16
46	Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 1161-1163.	2.4	16
47	Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1798-1802.	2.0	16
48	Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party. <i>American Journal of Hematology</i> , 2019, 94, 80-86.	4.1	16
49	Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD. <i>Blood Advances</i> , 2020, 4, 3927-3942.	5.2	16
50	Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study. <i>British Journal of Haematology</i> , 2021, 193, 814-826.	2.5	16
51	Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia. <i>Blood</i> , 2021, 137, 1697-1701.	1.4	15
52	Evaluation of Graft Versus Host Disease and Relapse Free Survival As Novel Endpoint in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Joint Naples-Paris Study. <i>Blood</i> , 2016, 128, 2285-2285.	1.4	15
53	Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation. <i>Haematologica</i> , 2021, 106, 2374-2383.	3.5	14
54	Stem Cell Transplantation for Diamond-Blackfan Anemia. A Retrospective Study on Behalf of the Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT). <i>Transplantation and Cellular Therapy</i> , 2021, 27, 274.e1-274.e5.	1.2	14

#	ARTICLE	IF	CITATIONS
55	Haploidentical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMT. American Journal of Hematology, 2021, 96, 571-579.	4.1	14
56	Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. Annals of Hematology, 2020, 99, 1855-1862.	1.8	13
57	Scoring system for clinically significant CMV infection in seropositive recipients following allogeneic hematopoietic cell transplant: an SFGM-TC study. Bone Marrow Transplantation, 2021, 56, 1305-1315.	2.4	13
58	Ruxolitinib for steroid-resistant acute GVHD. Blood, 2020, 135, 1721-1722.	1.4	12
59	Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the SocietÃ© FranÃ§aise de Greffe de Moelle et Therapie Cellulaire. Biology of Blood and Marrow Transplantation, 2015, 21, 1515-1523.	2.0	11
60	Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 1721-1724.	2.0	11
61	Design of the DREPAGREFFE trial: A prospective controlled multicenter study evaluating the benefit of genoidentical hematopoietic stem cell transplantation over chronic transfusion in sickle cell anemia children detected to be at risk of stroke by transcranial Doppler (NCT 01340404). Contemporary Clinical Trials, 2017, 62, 91-104.	1.8	11
62	Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1657-1663.	2.0	11
63	The effect of age in patients with acquired aplastic anaemia treated with immunosuppressive therapy: comparison of Adolescents and Young Adults with children and older adults. British Journal of Haematology, 2018, 183, 766-774.	2.5	11
64	HLA-DRB3/4/5 mismatches are associated with increased risk of acute GVHD in 10/10 matched unrelated donor hematopoietic cell transplantation. American Journal of Hematology, 2018, 93, 994-1001.	4.1	11
65	Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. Leukemia and Lymphoma, 2019, 60, 2802-2805.	1.3	10
66	Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas. Cancers, 2020, 12, 2856.	3.7	10
67	Stem Cell Transplantation for Diamond-Blackfan Anemia. a Retrospective Study on Behalf of Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT). Blood, 2019, 134, 44-44.	1.4	10
68	Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases. Blood Advances, 2020, 4, 6327-6335.	5.2	10
69	APRIL levels are associated with disease activity in human chronic graft-versus-host disease. Haematologica, 2016, 101, e312-e315.	3.5	9
70	Allogeneic stem cell transplantation for acquired pure red cell aplasia. American Journal of Hematology, 2019, 94, E294-E296.	4.1	9
71	Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2490-2500.	2.0	9
72	Early-onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failure. American Journal of Hematology, 2019, 94, E109-E111.	4.1	9

#	ARTICLE	IF	CITATIONS
73	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1160-1170.	2.0	9
74	Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 38-49.	2.4	9
75	Recommendations on hematopoietic stem cell transplantation for patients with Diamondâ€“Blackfan anemia. On behalf of the Pediatric Diseases and Severe Aplastic Anemia Working Parties of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2956-2963.	2.4	9
76	Cord blood transplantation for bone marrow failure syndromes: state of art. <i>Stem Cell Investigation</i> , 2019, 6, 39-39.	3.0	8
77	Clinical and economic impact of treated CMV infection in adult CMVâ€“seropositive patients after allogeneic hematopoietic cell transplantation. <i>Journal of Medical Virology</i> , 2020, 92, 3665-3673.	5.0	8
78	Severe Aplastic Anemia and PNH. , 2019, , 579-585.		8
79	GLCC1 and Glucocorticoid Receptor Genetic Diversity and Response to Glucocorticoid-Based Treatment of Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1246-1250.	2.0	7
80	Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation. <i>British Journal of Haematology</i> , 2019, 184, 294-298.	2.5	7
81	Aplastic anemia related to thymoma: a survey on behalf of the French reference center of aplastic anemia and a review of the literature. <i>Haematologica</i> , 2020, 105, e333-e336.	3.5	7
82	Upfront unrelated donor hematopoietic stem cell transplantation in patients with idiopathic aplastic anemia: A retrospective study of the Severe Aplastic Anemia Working Party of European Bone Marrow Transplantation. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	7
83	Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications. <i>American Journal of Hematology</i> , 2022, 97, 431-439.	4.1	7
84	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/â€“Tâ€“Cell lymphoma, nasal type: A French study from the SociÃ©tÃ© Francophone de Greffe de Moelle et de ThÃ©rapie Cellulaire (â€“SFGMâ€“TCâ€“). <i>American Journal of Hematology</i> , 2021, 96, 834-845.	4.1	5
85	Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 33-43.	2.4	5
86	Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures. <i>Science Translational Medicine</i> , 2022, 14, eabg3083.	12.4	5
87	Natural killer cell licensing after double cord blood transplantation is driven by the self-HLA class I molecules from the dominant cord blood. <i>Haematologica</i> , 2016, 101, e209-e212.	3.5	4
88	Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC. <i>Current Research in Translational Medicine</i> , 2019, 67, 8-15.	1.8	4
89	Risk factors for vascular liver diseases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 410-419.	1.5	4
90	Expansion of Circulating CD49b+LAG3+ Type 1 Regulatory T Cells in Human Chronic Graft-Versus-Host Disease. <i>Journal of Investigative Dermatology</i> , 2021, 141, 193-197.e2.	0.7	4

#	ARTICLE	IF	CITATIONS
91	Romiplostim in Patients Undergoing Allogeneic Stem Cell Transplantation: Results of a Phase I/II Multicenter Trial. <i>Blood</i> , 2016, 128, 65-65.	1.4	4
92	Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress. <i>Seminars in Hematology</i> , 2022, 59, 38-46.	3.4	4
93	Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive) Tj ETQq1 1 0.784314 rgBT /Overlock 6, 281.	3.5	3
94	Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1365-1372.	2.4	3
95	Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. <i>Leukemia Research</i> , 2017, 54, 12-16.	0.8	2
96	A Retrospective Chart Review to Assess Burden of Illness Among Patients with Severe Aplastic Anemia with Insufficient Response to Immunosuppressive Therapy. <i>Blood</i> , 2017, 130, 678-678.	1.4	2
97	Paroxysmal nocturnal hemoglobinuria and hematopoietic stem cell transplantation: Better results in 2015?. <i>Leukemia and Lymphoma</i> , 2016, 57, 740-741.	1.3	1
98	Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2018. <i>Leukemia Research</i> , 2019, 80, 19-25.	0.8	1
99	Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report. <i>Annals of Hematology</i> , 2020, 99, 897-898.	1.8	1
100	Assessment of chimerism and immunomodulation to prevent post-transplantation relapse in childhood acute myeloblastic leukemia: is it the right approach?. <i>Pediatric Hematology and Oncology</i> , 2020, 37, 259-268.	0.8	1
101	Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study. <i>Annals of Hematology</i> , 2020, 99, 743-752.	1.8	1
102	A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 4007-4007.	1.4	1
103	Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity. <i>Blood</i> , 2015, 126, 1985-1985.	1.4	1
104	Selecting Double Cord Blood Units for Adults with Hematological Malignancies: Impact of ABO, HLA and Cell Dose on Outcomes after Double Cord Blood Transplants a CBC-Cellular Therapy & Immunobiology Working Party, EBMT and Eurocord Study. <i>Blood</i> , 2015, 126, 3214-3214.	1.4	1
105	Nationwide Survey on the Use of Eltrombopag in Patients with Severe Aplastic Anemia: Report on Behalf of the French Reference Center for Aplastic Anemia. <i>Blood</i> , 2016, 128, 2684-2684.	1.4	1
106	Immunogenetic, Molecular and Clinical Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2021, 138, 602-602.	1.4	1
107	Gvhd and Relapse Free Survival (GRFS) after Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: An Analysis from the Saawp Data Quality Initiative Program of EBMT. <i>Blood</i> , 2020, 136, 3-4.	1.4	1
108	Adding eltrombopag to immunosuppression: the importance of predicting outcome. <i>Haematologica</i> , 2021, , .	3.5	0

#	ARTICLE	IF	CITATIONS
109	Secondary malignancies after transplantation for aplastic anemia. Bone Marrow Transplantation, 2021, 56, 2324-2325.	2.4	0
110	Initial Liver Involvement in Acute Graft-Versus-Host Disease (GVHD) Predicts a Severe Acute Gvhd and Poor Long-Term Survival. Blood, 2008, 112, 1164-1164.	1.4	0
111	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) as a Curative Therapy in Primary and Secondary Myelofibrosis (MF): A 14-Year Period Oligocentric French Experience.. Blood, 2008, 112, 1756-1756.	1.4	0
112	Outcome of Busulfan and Fludarabine-Based Reduced Intensity Conditioning Regimen for Related and Unrelated HSCT in Fanconi Anemia Patients. Blood, 2011, 118, 1964-1964.	1.4	0
113	Equivalent Outcome Between Reduced Intensity Versus Conventional Myeloablative Conditioning Hematopoietic Stem Cell Transplantation for Patients Older Than 35 Years with Acute Myeloid Leukemia.. Blood, 2012, 120, 3103-3103.	1.4	0
114	Risk Factors to Develop Sclerotic Chronic GvHD After Allogeneic HSCT: Preliminary Results of a Multicentre Retrospective study From the Societel-Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). Blood, 2012, 120, 1947-1947.	1.4	0
115	Influence of Stem Cell Source On GvH and NRM: Comparison of 10/10 HLA-Matched Unrelated Donor (MUD) with 9/10 HLA-Mismatched Unrelated Donor (MMUD) and Unrelated Cord Blood (UCB) Transplants.. Blood, 2012, 120, 3135-3135.	1.4	0
116	Lymphodepletion Followed By Suicide-Gene-Transduced Donor Lymphocyte Infusion: A Strategy To Safely Enhance The Graft-Versus-Tumor Effect. Blood, 2013, 122, 153-153.	1.4	0
117	Allogeneic Stem Cell Transplantation In Philadelphia Negative Myeloproliferative Or Myelodysplastic/Myeloproliferative Neoplasms: A Retrospective Analysis From The Societe FranÃ§aise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). Blood, 2013, 122, 3373-3373.	1.4	0
118	Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of Eurocord, SFGM-TC and Cqwp-EBMT. Blood, 2014, 124, 2581-2581.	1.4	0
119	Brentuximab Vedotin Followed By Allogeneic Stem-Cell Transplantation for Patients with CD30 Anaplastic or T Cell Non Hodgkin Lymphomas: A Study on Behalf of the SFGM-TC.. Blood, 2015, 126, 4377-4377.	1.4	0
120	Allogeneic Hematopoietic Stem Cell Transplantation Offers Similar Outcome after Myeloablative and Sequential Conditioning Regimen in Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia: A Study from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). Blood, 2015, 126, 4367-4367.	1.4	0
121	Skin Immune Stimulation By Infections and Drug Toxicities during Induction and/or Consolidations Increases Incidence of Skin Acute Graft Versus Host Disease in Acute Myeloid Leukemia: A Study on Behalf of SFGM-TC and ALFA. Blood, 2015, 126, 1946-1946.	1.4	0
122	CloB2A2 Reduced-Intensity Conditioning (RIC) Regimen Prior to Allogeneic Stem Cell Transplantation Provides Significant Better Survival Compared to FB2A2 RIC Regimen in Adults with Acute Myeloid Leukemia (AML): A Study on Behalf of the SFGM-TC. Blood, 2015, 126, 1908-1908.	1.4	0
123	Reduced-Intensity and Non-Myeloablative Allogeneic Stem Cell Transplantation from Alternative HLA-Mismatched Donors for Hodgkin's Lymphoma: A Study By the SFGM-TC (Francophone Society of Tj ETQq1 1 0.784314 rgBT /Ovsh	1.4	0
124	Reduced-Intensity (FB2) Vs Reduced-Toxicity Myeloablative (FB3/FB4) Fludarabine/Busulfan Based Conditioning Regimens for Non-Hodgkin Lymphoma (NHL) Allografted Adult Patients: A Retrospective Study on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Blood, 2016, 128, 980-980.	1.4	0
125	Incidence, Risk Factors and Outcome of Late Onset Noninfectious Pulmonary Complications after Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Cohort Study. Blood, 2016, 128, 4562-4562.	1.4	0
126	Triage Scoring System Based on Early Post-Transplant Complications for Patients with Myelodysplastic Syndrome Requiring ICU after Allo-HCT: An SFGM-TC Study. Blood, 2016, 128, 3470-3470.	1.4	0

#	ARTICLE	IF	CITATIONS
127	A Composite Event-Free Survival End Point to Evaluate Outcome after Allogeneic Transplantation for Severe Aplastic Anemia: A Study on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). <i>Blood</i> , 2016, 128, 2674-2674.	1.4	0
128	Outcome Analysis of High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma: A Francophone Society of Bone Marrow Transplantation and Cellular Therapy Study. <i>Blood</i> , 2016, 128, 3458-3458.	1.4	0
129	Allogeneic Stem Cell Transplantation in First Chronic Phase CML during the Last Decade: Retrospective Analysis of the National SFGM-TC Registry. <i>Blood</i> , 2016, 128, 3476-3476.	1.4	0
130	Aplastic Anemia in the Context of Hemolytic Paroxysmal Nocturnal Hemoglobinuria: Feasibility of Antibody-Based Intensive Immunosuppression during Eculizumab Treatment. <i>Blood</i> , 2016, 128, 5074-5074.	1.4	0
131	Single HLA Mismatch Unrelated Donor Allogeneic Stem Cell Transplantation in Caucasian Recipients: Outcomes in HLA-A, -B, -C, -DRB1 and -DQB1 Mismatch Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society for Histocompatibility and Immunogenetics (SFHI). <i>Blood</i> , 2016, 128, 3474-3474.	1.4	0
132	HCT Outcome in Patients with Fanconi Anemia Transplanted at Adult Age. <i>Blood</i> , 2016, 128, 4691-4691.	1.4	0
133	Allogeneic Stem Cell Transplantation in Fanconi Anemia and other inherited bone marrow failure disorders. <i>Current Drug Targets</i> , 2018, 19, .	2.1	0
134	Minimal Residual Disease in Ovarian Biopsies Collected in Patients with Bone Marrow Complete Remission of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 916-916.	1.4	0
135	Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab. <i>Blood</i> , 2018, 132, 625-625.	1.4	0
136	Upfront Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Idiopathic Aplastic Anemia: A Study on Behalf of the Saawp of EBMT. <i>Blood</i> , 2020, 136, 11-13.	1.4	0
137	Immunogenomics of Aplastic Anemia: The Role of HLA Somatic Mutations and the HLA Evolutionary Divergence. <i>Blood</i> , 2020, 136, 20-21.	1.4	0